The trial’s primary endpoint is the change in gout pain intensity from baseline in the target joint at day three.

ANI Pharma initiates phase 4 trial of purified Cortrophin Gel to treat acute gout flares: Princeton, New Jersey Friday, May 23, 2025, 14:00 Hrs [IST] ANI Pharmaceuticals, Inc., a ...

Sudeep Pharma Limited, a leading manufacturer of pharmaceutical and food-grade mineral ingredients, has announced the ...

Indian benchmark indices opened flat on Friday, showing signs of volatility mainly due to uncertain foreign portfolio ...

Pune-headquartered pharma company Emcure Pharmaceuticals on Thursday reported that its Profit After Tax or net profit in the ...

Emcure Pharmaceuticals reported a 63% surge in net profit for Q1 2025, reaching Rs 197 crore, compared to Rs 121 crore in the ...

Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2025 Earnings Call Transcript May 9, 2025 ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.7, expectations were $1.37.

ANI Pharmaceuticals has reported a strong first quarter for 2025, with earnings per share (EPS) of $1.70, significantly surpassing the forecasted EPS of $1.34. The company’s revenue reached $197.1 ...

May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2025. "We ...

Please stand by. Your program is about to begin. [Operator Instructions] Good day everyone and welcome to today's ANI Pharmaceuticals, Inc. First Quarter 2025 Earnings Results Call. Please note ...